PHARMACIE CONSCIENCE
ActiveThe computed 12-month bankruptcy probability of PHARMACIE CONSCIENCE is 1.5% (moderate). The 2024 annual accounts show equity of €40k and a net result of €27k. Equity is shrinking by ~22.1% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2027. Its solvency ranks better than 8% of 2792 sector peers (fiscal year 2024). The company has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
Axes · tick = 2023
Profitability100=
Solvency12▲+1
Growth32=
Stability100
Bankruptcy probability, 12 months
1.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €2k at 30 days acceptable
Liquidity short (current ratio 0.92 against 0.9 in 2023), and 96% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 8% of 2792 sector peers (2024).
NBB · sector comparisonPosition among 2792 sector peers
Solvency
better than 8%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-06-2025, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
31 d early
2023
28 d early
2022
27 d early
2021
59 d late
2020
30 d early
2019
31 d early
← before the deadline
after the deadline →
Financials · fiscal year 2024, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€27k▲ 33.0%
2023 · €21k
2018: €28k
2019: €16k
2020: €21k
2021: €6k
2022: €15k
2023: €21k
2018 → 2024
Working capital
€-32k▲ 10.5%
2023 · €-36k
2018: €-188k
2019: €-308k
2020: €-80k
2021: €-59k
2022: €-44k
2023: €-36k
2018 → 2024
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20202021202220232024Trend
Equity€88k-€54k▼ 38.9%€37k▼ 30.5%€38k▲ 1.7%€40k▲ 6.4%
Operating result€90k-€43k▼ 52.8%€67k▲ 57.5%€83k▲ 23.8%€89k▲ 6.7%
Net result€21k-€6k▼ 71.8%€15k▲ 151%€21k▲ 41.3%€27k▲ 33.0%
Result per fiscal year
Operating resultNet result
After the dip in 2021 the operating result has climbed three years in a row; 2024 is 7% above 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.01M
Fixed assets
€663k▼ 14.2%
Current assets
€352k▲ 3.7%
Equity and liabilities €1.01M
Equity
€40k▲ 6.4%
Debt
€974k▼ 9.3%
The debt ratio falls from 96.6% to 96.0%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€199k▲
2023 · €193k
Cash flow
€137k▲
2023 · €130k
Solvency
4.0%▲
2023 · 3.4%
Current ratio
0.92▲
2023 · 0.90
Quick ratio
0.52▲
2023 · 0.50
Debt / equity
24.09▼
2023 · 28.27
ROE
67.9%▲
2023 · 54.3%
ROA
2.7%▲
2023 · 1.9%
Interest coverage
7.17▲
2023 · 6.43
Debt
€974k▼
2023 · €1.07M
Debt ≤ 1 year
€384k▲
2023 · €375k
Debt > 1 year
€589k▼
2023 · €695k
Income taxes
€34k▲
2023 · €33k
Staff costs
€121k▼
2023 · €122k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2024 against 2023
Balance sheet
Code20232024
Assets
Total assets20/58€1.11M€1.01M▼
Fixed assets21/28€773k€663k▼
Intangible fixed assets21€422k€352k▼
Tangible fixed assets22/27€351k€311k▼
Land and buildings22€141k€136k▼
Plant, machinery and equipment23€194k€164k▼
Furniture and vehicles24€16k€11k▼
Financial fixed assets28€435€435=
Current assets29/58€339k€352k▲
Stocks and contracts in progress3€152k€150k▼
Stocks30/36€152k€150k▼
Amounts receivable within one year40/41€101k€126k▲
Trade receivables40€91k€92k▲
Other amounts receivable41€9k€34k▲
Current investments50/53€2k€2k=
Cash at bank and in hand54/58€80k€65k▼
Deferred charges and accrued income490/1€4k€9k▲
Equity and liabilities
Total equity and liabilities10/49€1.11M€1.01M▼
Equity10/15€38k€40k▲
Contributions10/11€19k€19k=
Reserves13€16k€16k=
Tax-exempt reserves132€9k€9k=
Distributable reserves133€8k€8k=
Profit (loss) carried forward14€3k€6k▲
Amounts payable17/49€1.07M€974k▼
Amounts payable after more than one year17€695k€589k▼
Financial debts170/4€695k€589k▼
Amounts payable within one year42/48€375k€384k▲
Current portion of amounts payable after more than one year42€111k€114k▲
Financial debts43€40k€29k▼
Credit institutions430/8€40k€29k▼
Trade debts44€169k€185k▲
Suppliers440/4€169k€185k▲
Taxes, remuneration and social security45€23k€31k▲
Taxes450/3€3k€5k▲
Remuneration and social security454/9€20k€26k▲
Other amounts payable47/48€33k€25k▼
Accrued charges and deferred income492/3€3k€985▼
Income statement
Code20232024
Remuneration, social security and pensions62€122k€121k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€110k€110k▲
Other operating charges640/8€20€0▼
Gross operating margin9900€315k€320k▲
Operating profit (loss)9901€83k€89k▲
Financial income75/76B-€410
Recurring financial income75-€410
Financial charges65/66B€30k€28k▼
Recurring financial charges65€30k€28k▼
Profit (loss) for the period before taxes9903€53k€61k▲
Income taxes67/77€33k€34k▲
Profit (loss) for the period9904€21k€27k▲
Profit (loss) for the period to be appropriated9905€21k€27k▲
Appropriation of the result
Profit (loss) to be appropriated9906€23k€31k▲
Profit (loss) brought forward from the previous period14P€3k€3k▲
Profit to be distributed694/7€20k€25k▲
Return on contributions (dividend)694€20k€25k▲
Social balance
Average headcount (FTE)90871.81.4▼
The notes to these accounts (12 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2025
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
03-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
04-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
28-09
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 59 days late
2021
31-12
Financial
Weakest financial yearnet €6k ▼71.8%
Net result drops to €6k, the lowest in the series; recovery starts the following year.
01-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
30-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
24-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
30-08
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 30 days late
2017
23-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 23 days late
2016
05-09
NBB filing
Annual accounts filed
fiscal year 2015 · full schema · 36 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
7 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Evere · 1 establishment unit since 2015
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
H. Consciencelaan 1491140 EvereGround area
125 m²
Building footprint
131 m²
Volume, LiDAR
1,172 m³
Parcel 21372D0200/00V008, Brussels · tallest building 15.9 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
Larpharma
since 20152.236.134.565
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21372D0200/00V008 | Brussels | 125 m² | 1 · 131 m² | 15.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
De Laere Pharma
BE 0763.546.683
Koksijde · Eq €40k
NP PHARMA
BE 1019.981.328
Mons · Eq €41k
PHARMACIE SCHOONEJANS
BE 0842.619.994
Sint-Gillis (bij-Brussel) · Eq €41k
SANASPE
BE 0874.832.607
Anderlecht · Eq €41k
APOTHEEK VAN SCHELVERGEM
BE 0448.130.892
Sint-Agatha-Berchem · Eq €40k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 2,439 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-08-2014
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
64200Holdings
64210Activities of holding companies
70200Business and other management consultancy
70220Business consulting
Sources
Crossroads Bank for EnterprisesNational Bank · 10 filingsAddress and cadastre registers
Data from official sources, last processed on 11-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
2 entriesE-mail:fedoualar@hotmail.com
Phone:0474/ 93 13 12